Stocks Health care ACAD
NASDAQ · Health careAcadia Pharmaceuticals Inc (ACAD)
Acadia Pharmaceuticals Inc brought in $1.2B of revenue over the twelve months to September 30, 2026, up 14.8% from a year earlier. Net income was $362.2M, a net margin of 30.1%. Operating cash flow minus capital spending left $105.1M of free cash flow in fiscal 2025. At September 30, 2026 it held $322.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Acadia Pharmaceuticals Inc
- Net worth
- Acadia Pharmaceuticals Inc has a market value (market cap) of $2.8B at the latest share price, and shareholders' equity of $1.4B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1.1B (+11.9% year on year), with net income of $391M. Over the 12 months to September 30, 2026: revenue $1.2B, net income $362.2M.
- Cash flow
- In fiscal 2025 operations brought in $109.8M of cash; after $4.7M of capital spending, free cash flow was $105.1M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Acadia Pharmaceuticals Inc's next report is expected around January 12, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Acadia Pharmaceuticals Inc does
Acadia Pharmaceuticals Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ACAD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.1B | $391M | $2.30 | $105.1M |
| 2024 | $957.8M | $226.5M | $1.36 | $157.2M |
| 2023 | $726.4M | -$61.3M | -$0.37 | $16.7M |
| 2022 | $517.2M | -$216M | -$1.34 | -$114M |
| 2021 | $484.1M | -$167.9M | -$1.05 | -$126.8M |
| 2020 | $441.8M | -$281.6M | -$1.79 | -$143.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ACAD ranks in Health care
Latest SEC filings
What Acadia Pharmaceuticals Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 23% to $342.3M versus the same quarter last year; diluted EPS $0.31 versus $0.42.
- November 4, 2026
- October 23, 2026
- September 24, 2026
- September 11, 2026Other event 8-K
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 16% to $308M versus the same quarter last year; diluted EPS $0.18 versus $0.16.
- August 4, 2026
- June 10, 2026
- May 29, 2026
What is ACAD worth? A DCF from its reported cash flow
Insider trades
What the people running Acadia Pharmaceuticals Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $69.3K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 30, 2026 | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | Soldpre-planned (10b5-1) | 3,321 | $69.3K |
| October 15, 2026 | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | Received as pay | 6,815 | - |
| August 6, 2026 | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | Exercised options | 14,292 | $255K |
| August 6, 2026 | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | Soldpre-planned (10b5-1) | 5,000 | $145K |
| August 6, 2026 | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | Soldpre-planned (10b5-1) | 9,292 | $272.6K |
| August 5, 2026 | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | Exercised options | 5,849 | $104.3K |
| August 5, 2026 | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | Soldpre-planned (10b5-1) | 5,849 | $169.6K |
| July 30, 2026 | Thompson Elizabeth H.Z.EVP, Head of Research & Dev | Soldpre-planned (10b5-1) | 16,508 | $431.4K |
Who owns ACAD
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Julian C. Baker13D, may seek influence with 4 related filers | 25.4% | February 26, 2026 |
| Vanguard Portfolio Management13G, passive | 5.15% | April 28, 2026 |
Largest institutional holders
Insiders
12 insiders reported holding 39,660,979 shares in total, about $654.4M at the last price.
| Holder | Shares |
|---|---|
| Baker Bros. Advisors LPDirector, 10% owner | 39,384,58739,384,587 held indirectly |
| Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | 71,322 |
| Harrigan EdmundDirector | 43,148 |
| Garofalo Elizabeth A.Director | 33,489 |
| Ndu AdoraDirector | 32,908 |
| Brege LauraDirector | 23,202 |
| Thompson Elizabeth H.Z.EVP, Head of Research & Dev | 18,994 |
| Owen Adams CatherineChief Executive Officer, Director | 14,803 |
| Kihara JamesPRINCIPAL ACCOUNTING OFFICER | 13,088 |
| Daly James MDirector | 12,148 |
Questions about ACAD
What does Acadia Pharmaceuticals Inc do?
Acadia Pharmaceuticals Inc is a company in the Health care sector, listed on NASDAQ as ACAD. Its shares trade on NASDAQ under the ticker ACAD.
What is Acadia Pharmaceuticals Inc's net worth?
Acadia Pharmaceuticals Inc has a market value (market cap) of $2.8B at the latest share price, and shareholders' equity of $1.4B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Acadia Pharmaceuticals Inc profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $362.2M on revenue of $1.2B, a net margin of 30.1%.
How much revenue does Acadia Pharmaceuticals Inc make?
Over the twelve months to September 30, 2026 Acadia Pharmaceuticals Inc reported revenue of $1.2B. That is 14.8% more than a year earlier.
When did Acadia Pharmaceuticals Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Acadia Pharmaceuticals Inc's next earnings report?
Acadia Pharmaceuticals Inc's next report is expected around January 12, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ACAD with
Follow ACAD
Get an email when Acadia Pharmaceuticals Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Acadia Pharmaceuticals Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.